Share This Article:

Short-Term Outcomes in Heart Transplant Recipients Treated with Generic Tacrolimus Compared to Prograf

Abstract Full-Text HTML Download Download as PDF (Size:37KB) PP. 19-21
DOI: 10.4236/ojots.2013.32004    3,536 Downloads   6,018 Views   Citations

ABSTRACT

Calcineurin inhibitors are the cornerstone of solid organ transplant immunosuppression. Tacrolimus has only recently become available in a non-branded formulation, and there is little data on the efficacy and safety of generic tacrolimus, particularly following heart transplant. We performed a retrospective analysis of 21 consecutive patients who were treated with generic tacrolimus following heart transplant and compared rate of biopsy-proven acute cellular rejection to historical controls who were treated with Prograf. No significant difference in biopsy-proven acute cellular rejection was noted between the groups and rates of opportunistic infection and death were comparable. Although limited by the single-center, retrospective design, this preliminary data may be useful to clinicians facing the option of initiating generic tacrolimus following heart transplant.


Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Dhungel, V. , Colvin-Adams, M. and Eckman, P. (2013) Short-Term Outcomes in Heart Transplant Recipients Treated with Generic Tacrolimus Compared to Prograf. Open Journal of Organ Transplant Surgery, 3, 19-21. doi: 10.4236/ojots.2013.32004.

References

[1] J. Stehlik, L. B. Edwards, A. Y. Kucheryavaya, P. Aurora, J. D. Christie, R. Kirk, et al., “The Registry of the International Society for Heart and Lung Transplantation: Twenty-Seventh Official Adult Heart Transplant Report—2010,” The Journal of Heart and Lung Transplantation, Vol. 29, No. 10, 2010, pp. 1089-1103. doi:10.1016/j.healun.2010.08.007
[2] P. A. Uber, H. J. Ross, A. O. Zuckermann, S. C. Sweet, P. A. Corris, K. McNeil, et al., “Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory,” The Journal of Heart and Lung Transplantation, Vol. 28, No. 7, 2009, pp. 655-660. doi:10.1016/j.healun.2009.05.001
[3] H. A. Abdulnour, C. E. Araya and V. R. Dharnidharka, “Comparison of Generic Tacrolimus and Prograf Drug Levels in a Pediatric Kidney Transplant Program: Brief Communication,” Pediatric Transplantation, Vol. 14, No. 8, 2010, pp. 1007-1011. doi:10.1111/j.1399-3046.2010.01393.x
[4] J. A. Petan, N. Undre, M. R. First, K. Saito, T. Ohara, O. Iwabe, et al., “Physiochemical Properties of Generic Formulations of Tacrolimus in Mexico,” Transplantation Proceedings, Vol. 40, No. 5, 2008, pp. 1439-1442. doi:10.1016/j.transproceed.2008.03.091

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.